Baptist Health completes first procedure in new brain aneurysm clinical trial
Jacksonville, FL
Baptist Health completed its first procedure as part of the PIONEER study, an international clinical trial evaluating a next generation flow-diverting stent designed specifically to treat unruptured brain aneurysms located in small blood vessels and harder-to-reach areas.
A brain aneurysm is a weak, bulging spot in the wall of an artery inside or around the brain that fills with blood. If it ruptures, the bleeding can cause a life-threatening stroke.
The minimally invasive procedure involves implanting a tiny mesh tube, called the Silk Baby Vista Flow Diverter, into blood vessels measuring just 1.5 to 3 mm in diameter, about the thickness of a credit card to two stacked dimes. The device is delivered through a tiny microcatheter, which is what facilitates its use in smaller vessels. Then, the device is implanted in an artery to help redirect blood flow away from the weakened area of the brain and reduce the pressure causing an aneurysm. Over time, the aneurysm can seal off and heal, lowering the risk of a rupture.
Known treatment, new possibility
Flow diversion is a common treatment for many brain aneurysms, but existing devices are designed for larger arteries.
“For years, we’ve had excellent tools to treat brain aneurysms in large vessels, but some aneurysms form in smaller vessel, making them more challenging to treat,” explained Eric Sauvageau, MD, neurosurgeon, co-medical director of the Baptist Stroke & Cerebrovascular Center and investigator in the PIONEER study. “This study is evaluating a technology designed specifically for aneurysms in smaller vessels, with the potential to expand treatment possibilities for patients who may have had limited options in the past.”
Bringing research home
While the device is available in Europe, it is not yet approved by the Food and Drug Administration (FDA) for widespread use the U.S. The PIONEER study has FDA IDE approval G250235, NCT NCT07225075. Through the PIONEER clinical trial, eligible patients at Baptist Health and other trial sites have access to this technology while researchers evaluate its effectiveness as part of the FDA approval process. Baptist Health is one of only 40 participating sites in the U.S. and five sites in Canada.
“Clinical research allows us to bring emerging innovations to our patients before they become widely available,” said Ricardo A. Hanel, MD, PhD, neurosurgeon, co-medical director of the Baptist Stroke & Cerebrovascular Center and international principal investigator of the study. “Our goal is not only to deliver excellent care today, but to help shape the future of care for patients throughout the U.S. Studies like PIONEER allow us to evaluate emerging technologies, expand access to advanced treatment options and help determine how aneurysm care evolves in the years ahead.”
To learn more about research at Baptist Health, visit Baptist Health Research Institute.